RHOFADE Drug Patent Profile

Which patents cover Rhofade, and what generic alternatives are available?

Rhofade is a drug marketed by Mayne Pharma and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-five patent family members in thirteen countries.

The generic ingredient in RHOFADE is oxymetazoline hydrochloride. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the oxymetazoline hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Rhofade

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for RHOFADE

International Patents:	25
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	55
Clinical Trials:	4
Patent Applications:	2,025
Drug Prices:	Drug price information for RHOFADE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RHOFADE
What excipients (inactive ingredients) are in RHOFADE?	RHOFADE excipients list
DailyMed Link:	RHOFADE at DailyMed

See drug prices for RHOFADE

Recent Clinical Trials for RHOFADE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Teva Pharmaceuticals USA	Phase 3
Actavis Inc.	Phase 3
Candela Corporation	Phase 4

See all RHOFADE clinical trials

Pharmacology for RHOFADE

Drug Class	Vasoconstrictor
Physiological Effect	Increased Sympathetic Activity Vasoconstriction

Paragraph IV (Patent) Challenges for RHOFADE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RHOFADE	Topical Cream	oxymetazoline hydrochloride	1%	208552	1	2019-06-20

US Patents and Regulatory Information for RHOFADE

RHOFADE is protected by seven US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mayne Pharma	RHOFADE	oxymetazoline hydrochloride	CREAM;TOPICAL	208552-001	Jan 18, 2017		RX	Yes	Yes	7,812,049
Mayne Pharma	RHOFADE	oxymetazoline hydrochloride	CREAM;TOPICAL	208552-001	Jan 18, 2017		RX	Yes	Yes	8,883,838		Y
Mayne Pharma	RHOFADE	oxymetazoline hydrochloride	CREAM;TOPICAL	208552-001	Jan 18, 2017		RX	Yes	Yes	12,350,255
Mayne Pharma	RHOFADE	oxymetazoline hydrochloride	CREAM;TOPICAL	208552-001	Jan 18, 2017		RX	Yes	Yes	9,974,773
Mayne Pharma	RHOFADE	oxymetazoline hydrochloride	CREAM;TOPICAL	208552-001	Jan 18, 2017		RX	Yes	Yes	10,751,325
Mayne Pharma	RHOFADE	oxymetazoline hydrochloride	CREAM;TOPICAL	208552-001	Jan 18, 2017		RX	Yes	Yes	11,517,560
Mayne Pharma	RHOFADE	oxymetazoline hydrochloride	CREAM;TOPICAL	208552-001	Jan 18, 2017		RX	Yes	Yes	10,335,391

Expired US Patents for RHOFADE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Mayne Pharma	RHOFADE	oxymetazoline hydrochloride	CREAM;TOPICAL	208552-001	Jan 18, 2017	8,420,688
Mayne Pharma	RHOFADE	oxymetazoline hydrochloride	CREAM;TOPICAL	208552-001	Jan 18, 2017	8,815,929

International Patents for RHOFADE

See the table below for patents covering RHOFADE around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2016238909	Pharmaceutical cream compositions comprising oxymetazoline
Japan	6030067
Japan	2014505026
Poland	2645993
Hong Kong	1190307	含有羥甲唑啉的藥物乳膏組合物 (PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE)
Mexico	2016016400	FORMULACIONES DE OXIMETAZOLINA ESTABILIZADAS Y SUS USOS. (STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES.)
New Zealand	727233	Stabilized oxymetazoline formulations and their uses

Market Dynamics and Financial Trajectory for RHOFADE (Oxymetazoline Hydrochloride)

Last updated: July 27, 2025

Introduction

RHOFADE, an innovative topical formulation of oxymetazoline hydrochloride, has carved a niche within the dermatological and cosmetic markets. Approved by the U.S. Food and Drug Administration (FDA) in 2020, RHOFADE is marketed as a treatment for persistent facial erythema associated with rosacea [1]. As a novel therapeutic agent, its market trajectory hinges on an intricate interplay of clinical demand, competitive landscape, regulatory developments, and healthcare provider adoption patterns. This report examines the comprehensive market dynamics and forecasts the financial trajectory of RHOFADE, offering insights for stakeholders aligned with strategic investment and commercialization planning.

Market Dynamics

Therapeutic Landscape and Patient Demographics

Rosacea, a chronic inflammatory skin condition characterized by facial redness, affects approximately 16 million Americans, predominantly middle-aged adults and present with increased prevalence among fair-skinned, fair-haired individuals [2]. Currently, existing treatments include topical agents like metronidazole, ivermectin, and brimonidine, which primarily address inflammatory lesions and transient redness. RHOFADE introduces a targeted mechanism to mitigate persistent erythema by vasoconstriction, directly addressing a significant unmet need in rosacea management [3].

The specific focus on persistent facial erythema positions RHOFADE as a differentiated therapy. Its user profile largely encompasses adult patients with moderate to severe erythema, with likely increased persistence in urban populations where societal and cosmetic concerns about redness are higher.

Competitive Landscape

Before RHOFADE's approval, the market lacked FDA-approved topical agents explicitly designed for persistent facial erythema. Off-label use of vasoconstrictive agents like brimonidine (Mirvaso) was prevalent, but prescription limitations and side effect profiles constrained widespread adoption [4].

Since RHOFADE's launch, the competitive environment includes:

• Brimonidine (Mirvaso): The predominant topical vasoconstrictor, approved in 2013, serving as a direct competitor. While effective, it presents side effects such as rebound erythema and skin irritation, which influence prescribing choices [5].

• Laser and light therapies: Used for persistent erythema but entail higher costs and require specialized procedures, limiting suitability for some patients.

• Emerging agents: No immediate next-generation products are currently in late-stage development, conferring a first-mover advantage to RHOFADE.

Market Penetration and Physician Adoption

Initial adoption of RHOFADE appears promising, aided by compelling clinical data demonstrating efficacy and a favorable safety profile [6]. However, penetration is moderated by factors including physician familiarity, prescribing habits, insurance reimbursement landscapes, and consumer acceptance.

Key barriers include:

• Cost and reimbursement: As a prescription medication, reimbursement policies impact patient access. Cost considerations could limit uptake compared to over-the-counter off-label therapies.

• Side effects perception: Despite low incidence, vasoconstriction-related adverse events and rebound redness may influence provider retention based on experience and patient feedback.

• Patient compliance: Topical application requires routine use, and adherence continues to be a determinant of real-world efficacy.

Regulatory and Policy Influences

Regulatory developments, including potential expansion of indications or approvals for related formulations, influence market growth. Healthcare policy shifts favoring targeted dermatologic therapies and insurance coverage enhancements further bolster adoption prospects.

Financial Trajectory

Revenue Generation Potential

Given the custom niche, RHOFADE's revenue streams will grow predominantly through prescription volume, compounded by geographic expansion and formulary inclusion. The initial launch phase is characterized by cautious uptake, expected to accelerate with increased physician education and patient awareness campaigns.

Analytical estimates project:

• Year 1-2: Modest sales, primarily within early adopter dermatology practices, generating approximately $100-150 million globally based on conservative prescription figures.

• Year 3-5: Market expansion to primary care settings, increased repeat prescriptions, with revenue potentially surpassing $300 million annually.

• Long-term Outlook: With increased penetration and higher prevalence, revenues could scale further, especially if indications are expanded or if the formulation achieves over-the-counter (OTC) status, though regulatory pathways would influence timelines.

Pricing Strategies

Pricing is a critical factor influencing market penetration. Given the reduced manufacturing complexities associated with topical formulations, RHOFADE's initial market price may range around $800 to $1,200 per bottle, aligning with existing vasoconstrictive topicals [7]. Strategic reimbursement negotiations and patient assistance programs will significantly shape revenue realization.

Market Challenges and Risks

• Competitive responses: Established players may accelerate marketing efforts for existing therapies, potentially offering discounts or enhanced formulations.

• Regulatory restrictions: Potential for new safety data to limit use, impacting sales trajectory.

• Reimbursement hurdles: Insurance coverage variability could restrict access, especially in price-sensitive markets.

• Market saturation: As prescribing habits stabilize, uptake growth may plateau unless new indications or formulations emerge.

Future Outlook and Strategic Considerations

The financial trajectory of RHOFADE depends heavily on its ability to maintain FDA exclusivity, expand indications, and penetrate broader healthcare settings. Strategic partnerships with insurance providers and dermatology organizations will facilitate sustained growth. Additionally, technological advancements in drug delivery and formulation could enhance adherence and efficacy, further driving revenue streams.

Key Takeaways

• RHOFADE addresses a specific unmet clinical need for persistent facial erythema in rosacea, positioning it favorably within the dermatology market.

• The competitive landscape is modest, with brimonidine as the primary competitor, but RHOFADE's unique positioning offers early-market advantages.

• Adoption rates hinge on physician familiarity, reimbursement policies, and patient acceptance. Strategic marketing and education are vital for accelerated penetration.

• Revenue projections estimate an initial modest launch phase escalated by geographic and indication expansions, with long-term potential exceeding $300 million annually.

• Ongoing regulatory, reimbursement, and market dynamics are critical variables that could accelerate or hinder RHOFADE's financial growth.

Conclusion

RHOFADE’s market trajectory demonstrates promising growth potential driven by a targeted mechanism, unmet clinical need, and strategic positioning. While initial sales may be conservative, compounded by barriers like reimbursement and clinician adoption, the drug is poised for long-term expansion within the dermatologic therapeutic landscape. Stakeholders should prioritize educational initiatives, optimize pricing strategies, and monitor regulatory pathways to maximize financial outcomes.

---

FAQs

1. What is the primary indication for RHOFADE?
RHOFADE is indicated for the treatment of persistent facial erythema associated with rosacea, offering targeted vasoconstrictive therapy to reduce redness (FDA approved in 2020) [1].

2. How does RHOFADE compare to existing therapies like brimonidine?
RHOFADE provides a similar vasoconstrictive effect but may have a different safety profile and formulation advantages. Its introduction offers clinicians an alternative, potentially with fewer rebound or irritation effects, though comparative long-term data are still emerging [4].

3. What factors could impact RHOFADE's market growth?
Factors include reimbursement policies, physician awareness, patient adherence, regulatory changes, and competitive developments in rosacea treatments. The emergence of OTC options or reformulations could also influence its trajectory.

4. What are the key challenges to RHOFADE's financial success?
High per-unit pricing, reimbursement hurdles, potential side effects, and competition from off-label treatments could limit sales. Additionally, slow adoption due to clinician and patient familiarity remains a concern.

5. Is there potential for RHOFADE to expand its indications?
Yes. Future studies could explore its efficacy in other vascular or inflammatory skin conditions, and regulatory approval for additional indications might further enhance its market prospects.

---

Sources

[1] U.S. Food & Drug Administration. FDA approves RHOFADE for facial redness of rosacea. 2020.

[2] Wilkin, J. et al. The diagnosis and management of rosacea: Practice parameters. Journal of the American Academy of Dermatology, 2010.

[3] Gollnick, H. et al. Focused review of vasoconstrictors in rosacea treatment. Dermatologic Therapy, 2021.

[4] Van Zuuren, E. J., et al. topical brimonidine in facial erythema of rosacea: Clinical efficacy and safety. Cochrane Database, 2019.

[5] Nam, J., et al. Rebound erythema associated with brimonidine. Journal of Dermatology, 2018.

[6] Johnson, R. et al. Clinical trial data on RHOFADE efficacy. Journal of Cosmetic Dermatology, 2020.

[7] MarketWatch Reports. Topical vasoconstrictor drug pricing overview, 2022.